Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which ablation works best for AFib with heart failure? new trial aims to find out

NCT ID NCT07153718

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study compares three catheter ablation strategies in 300 adults with persistent atrial fibrillation and heart failure. The goal is to see which approach best reduces the risk of death, hospitalization, or urgent visits due to worsening heart failure. Participants are randomly assigned to one of three ablation procedures, and their heart rhythm and outcomes are tracked over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter ablation (a procedure to destroy abnormal heart tissue causing irregular rhythm)
What this could lead to
If successful, this could identify the best ablation approach to improve survival and reduce hospitalizations for people with both atrial fibrillation and heart failure.
What could go wrong
This is a mid-stage trial with 300 participants, so results may not apply to everyone. Ablation carries risks like bleeding, infection, or heart rhythm complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Jan 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All inclusion criteria must be met to be included in the study. 1. Age: Patients aged 18-80 years, with persistent atrial fibrillation (AF) and heart failure (HF), regardless of ejection fraction (EF). 2. Diagnosis of Heart Failure: Heart Failure with Reduced Ejection Fraction (HFrEF): LVEF ≤ 40%. Heart Failure with Preserved Ejection Fraction (HFpEF): LVEF \> 40%, including HFmrEF (LVEF 41-50%). 3. Symptomatic Atrial Fibrillation: Patients with symptomatic persistent AF who have failed or are intolerant to at least one antiarrhythmic drug. 4. NYHA Class II-III: Patients with heart failure classified as NYHA class II-III, who are symptomatic despite optimal medical therapy. Informed Consent: Able to provide written informed consent for participation in the study. 5. Guideline-Recommended Pharmacologic Therapy: Patients who have received and are currently on guideline-recommended pharmacologic therapy for heart failure, including but not limited to ACE inhibitors, beta-blockers, diuretics, and mineralocorticoid receptor antagonists (MRAs). Exclusion Criteria: * Any of the following criteria shall be excluded. 1. End-Stage Heart Failure: Patients with heart failure classified as NYHA class IV or with LVEF ≤ 20%. 2. Severe Comorbidities: 3. Patients with severe pulmonary disease (e.g., COPD, severe restrictive lung disease). 4. Severe renal dysfunction (eGFR \< 30 mL/min/1.73m²) or advanced liver disease. 5. Active malignancy or other terminal illnesses with a prognosis of less than one year. 6. Inability to Tolerate Ablation: <!-- --> 1. Patients unable to undergo catheter ablation due to anatomical or procedural issues. 2. Patients with contraindications to the procedure, including allergy to contrast agents or inability to tolerate anesthesia. 3. Left atrial thrombus confirmed by preoperative esophageal ultrasound; 7. Uncontrolled Arrhythmias: Patients with persistent or paroxysmal AF who are unable to maintain sinus rhythm despite optimal medical therapy or require frequent hospitalization for arrhythmia control. 8\. Pregnancy: Pregnant or breastfeeding women. 9. Contraindications to Anticoagulation: 10. Patients who are contraindicated for anticoagulation therapy (e.g., history of major bleeding or bleeding diathesis). 11\. History of Severe Valve Disease: Patients with a history of severe valve disease and/or prosthetic valve replacement. 12\. Recent Myocardial Infarction or Stroke: Patients who have had a myocardial infarction or stroke within the past 3 months. 13\. Contrast Agent Allergy: Patients with a known allergy to contrast agents. 14. Contraindications for Cardiac Catheterization: Any contraindications for cardiac catheterization, including inability to safely perform the procedure. 15\. Atrial Fibrillation Ablation: Patients who have previously undergone atrial fibrillation ablation. 16\. Cardiac Surgery: Patients who have undergone any cardiac surgery within the last 2 months. 17\. Life Expectancy: Patients with a life expectancy of less than 1 year.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, 272000, China

  • Changshu Hospital of Traditional Chinese Medicine

    Changshu, Jiangsu, 215516, China

  • Jinan City People's Hospital

    Jinan, Shandong, 271100, China

  • Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, 200127, China

  • Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine

    Jinan, Shandong, 250000, China

  • Shanghai Jiao Tong University School of Medicine, Shanghai Chest Hospital

    Shanghai, 200030, China

  • The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430014, China

  • The PLA Navy Anqing Hospital

    Anqing, Anhui, 246000, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, 221009, China

  • Yuhuan Second People's Hospital

    Yuhuan, Zhejiang, 317600, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.